Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug;19(8):851-9.
doi: 10.1634/theoncologist.2014-0105. Epub 2014 Jun 26.

Adjuvant therapy for renal cell carcinoma: past, present, and future

Sumanta K Pal  1 , Naomi B Haas  2
Affiliations
Review

Adjuvant therapy for renal cell carcinoma: past, present, and future

Sumanta K Pal et al. Oncologist. 2014 Aug.

Abstract
in English, Chinese

At the present time, the standard of care for patients who have received nephrectomy for localized renal cell carcinoma (RCC) is radiographic surveillance. With a number of novel targeted agents showing activity in the setting of metastatic RCC, there has been great interest in exploring the potential of the same agents in the adjuvant setting. Herein, we discuss the evolution of adjuvant trials in RCC, spanning from the immunotherapy era to the targeted therapy era. Pitfalls of current studies are addressed to provide a context for interpreting forthcoming results. Finally, we outline avenues to incorporate promising investigational agents, such as PD-1 (programmed death-1) inhibitors and MNNG transforming gene inhibitors, in future adjuvant trials.

摘要

目前，对因局部肾细胞癌 (RCC) 接受过肾切除术的患者所施用的标准治疗是影像学监测。随着一些新型靶向制剂在转移性 RCC 治疗中表现出活性，研究人员对探索相同制剂用于辅助治疗的可能性产生了很大兴趣。在本文中，我们讨论了 RCC 辅助治疗试验的发展，从免疫治疗时代跨越到靶向治疗时代。当前研究的难点在于为解读即将获得的结果提供背景。最后，我们概述了在将来的辅助治疗试验中纳入颇具希望的试验性制剂的途径，例如 PD-1（程序性死亡分子-1）抑制剂和 MNNG 转化基因抑制剂。 (The Oncologist) 2014;19:851–859

Keywords: ASSURE; Adjuvant; EVEREST; PROTECT; Renal cell carcinoma; S-TRAC; SORCE.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1.
Figure 1.
A proposed schema for neoadjuvant/adjuvant clinical trials incorporating PD-1 inhibitors. Abbreviation: RCC, renal cell carcinoma.
Figure 2.
Figure 2.
Schema for PrE0801 (NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition [TKI] at Recurrence After Adjuvant Therapy in RCC). Abbreviation: RCC, renal cell carcinoma.
See this image and copyright information in PMC

References

    1. Pal SK, Williams S, Josephson DY, et al. Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther. 2012;11:526–537. - PMC - PubMed
    1. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet. 2011;378:1931–1939. - PubMed
    1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134. - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124. - PubMed
    1. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068. - PubMed

Publication types

MeSH terms

Substances